RPT-DEALTALK-Drug overlaps, shortages may complicate Teva bid for Mylan
April 26, 2015 at 08:00 AM EDT
NEW YORK, April 24 (Reuters) - Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings.